MoneyDiscourse
← All companies

PFE

PFIZER INC · Health Care

8 quarters · 53 figures · latest Q3 FY2026 filed 2026-11-03 →

Compared

6 of 8 · select any line below to add or remove it ·

  • TOTAL REVENUES

    $16.58bn−0.4% Y/Y

    Q3 FY2026

  • Reported Net Income

    $3.24bn−8.4% Y/Y

    Q3 FY2026

  • Reported Diluted EPS

    $0.56−9.7% Y/Y

    Q3 FY2026

  • Acquired in-process research and development expenses

    $669m−51.9% Y/Y

    Q3 FY2026

  • Alliance revenues

    $2.85bn+24.1% Y/Y

    Q3 FY2026

  • Amortization of intangible assets

    $1.13bn−7.8% Y/Y

    Q3 FY2026

Reported figures

Click any line for its full history. Each figure links to the filing it was read from.

Income statement

25 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Acquired in-process research and development expensesacquired_iprd_expense
$212m$137m$16m$669m−51.9%+4081.3%
Alliance revenuesalliance_revenue
$2.58bn$2.34bn$2.7bn$2.85bn+24.1%+5.7%
Amortization of intangible assetsamortization_of_intangibles
$1.23bn$1.18bn$1.19bn$1.13bn−7.8%−4.8%
Cost of salescost_of_sales
$5.27bn$3.55bn$4.09bn$4.03bn−3.5%−1.6%
Adjusted Cost of Salescost_of_sales_non_gaap
$5.07bn$3.41bn$3.66bn$3.84bn−3.4%+5.1%
Reported Diluted EPSeps_diluted
−$0.29$0.47−$0.04$0.56−9.7%+1500.0%
Adjusted Diluted EPSeps_diluted_non_gaap
$0.66$0.75$0.77$0.87+0.0%+13.0%
Provision/(benefit) for taxes on incomeincome_tax_provision
−$2m$461m−$407m$134m+162.0%+132.9%
Reported Net Incomenet_income
−$1.65bn$2.69bn−$248m$3.24bn−8.4%+1407.3%
Adjusted Incomenet_income_non_gaap
$3.79bn$4.29bn$4.44bn$4.99bn+0.7%+12.3%
Income from continuing operations before provision/(benefit) for taxes on incomepretax_income
−$1.64bn$3.17bn−$653m$3.39bn+1.5%+618.4%
Product revenuesproduct_revenue
$14.5bn$11.72bn$11.86bn$13.26bn−4.8%+11.7%
Research and development expensesrd_expense
$3.21bn$2.49bn$2.81bn$3.02bn+18.5%+7.4%
Adjusted R&D Expensesrd_expense_non_gaap
$3.12bn$2.43bn$2.73bn$2.94bn+18.3%+7.8%
Restructuring charges and certain acquisition-related costsrestructuring_and_acquisition_costs
$604m$100m$457m$791m+176.6%+73.1%
Royalty revenuesroyalty_revenue
$480m$396m$474m$477m+9.4%+0.6%
Selling, informational and administrative expensessga_expense
$4.16bn$2.96bn$3.41bn$3.28bn+2.9%−3.9%
Adjusted SI&A Expensessga_expense_non_gaap
$4.08bn$2.92bn$3.34bn$3.22bn+2.0%−3.7%
TOTAL REVENUEStotal_revenue
$17.56bn$14.45bn$15.03bn$16.58bn−0.4%+10.3%
Diluted weighted-average shares (millions)diluted_shares
—5,7315,6995,751+0.6%+0.9%
Other (income)/deductions––netother_income_deductions_net
—$861m$3.72bn$288m−44.3%−92.2%
Adjusted Other (Income)/Deductions—netother_income_deductions_net_non_gaap
—$388m$108m$102m−60.3%−5.6%
Income/(loss) from continuing operationsincome_from_continuing_operations
−$1.64bn———−499.0%—
Other (Income)/Deductions—netother_deductions_net
$4.51bn———+91.4%—
Adjusted Other (Income)/Deductions—netother_deductions_net_non_gaap
$139m———−40.6%—

Segments

12 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Oncologyoncology_revenue
$4.44bn$3.83bn$4.17bn$4.33bn+9.9%+3.9%
Primary Careprimary_care_revenue
$7.94bn$5.54bn$5.5bn$6.97bn−8.8%+26.7%
Global Biopharmaceuticals Business (Biopharma)segment_biopharma_revenue
$17.14bn$14.16bn$14.66bn$16.28bn−0.2%+11.1%
Pfizer CentreOnesegment_pfizer_centreone_revenue
$409m$289m$373m$300m−12.8%−19.6%
Specialty Carespecialty_care_revenue
$4.77bn$2.94bn$3.35bn$3.35bn+7.0%−0.1%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISIONglobal_hospital_biosimilars_division_revenue
—$1.24bn$1.16bn$1.17bn+9.0%+0.9%
Hospital and Biosimilarshospital_and_biosimilars_revenue
—$1.85bn$1.64bn$1.64bn+2.2%−0.3%
PFIZER INTERNATIONAL COMMERCIAL DIVISIONinternational_commercial_division_revenue
—$5.23bn$5.54bn$5.43bn+1.0%−2.0%
Total International revenuesinternational_revenue
—$5.72bn$6.18bn$5.98bn+0.3%−3.2%
PFIZER U.S. COMMERCIAL DIVISIONus_commercial_division_revenue
—$7.69bn$7.96bn$9.68bn−1.8%+21.6%
United States total revenuesus_revenue
—$8.73bn$8.86bn$10.6bn−0.8%+19.7%
Pfizer Ignitesegment_pfizer_ignite_revenue
$4m———−84.6%—

Operating

12 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Comirnatycomirnaty_revenue
$2.27bn$232m$261m$808m−29.8%+209.6%
Eliquiseliquis_revenue
$2.02bn$2.17bn$2.43bn$2.52bn+25.2%+4.0%
Ibranceibrance_revenue
$1.04bn$1.01bn$1.06bn$1.08bn+2.4%+2.3%
Nurtec ODT/Vyduranurtec_revenue
$405m$353m$421m$547m+32.8%+29.9%
Padcevpadcev_revenue
$508m$591m$667m$720m+55.2%+7.9%
Paxlovidpaxlovid_revenue
$218m$186m$21m$449m−63.3%+2038.1%
Prevnar familyprevnar_family_revenue
$1.71bn$1.69bn$1.34bn$1.56bn−10.2%+17.0%
Vyndaqel familyvyndaqel_family_revenue
$1.69bn$1.6bn$1.76bn$1.77bn+11.4%+0.6%
Abrysvoabrysvo_revenue
$481m—$208m$303m+8.6%+45.7%
Lorbrenalorbrena_revenue
$282m—$354m$387m+44.4%+9.3%
Xtandixtandi_revenue
$592m—$534m$541m−6.4%+1.3%
Oncology biosimilarsoncology_biosimilars_revenue
$369m———+76.6%—

Margins

4 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Cost of Sales Percent of Revenuescost_of_sales_pct_revenue
30.0%24.6%27.2%24.3%−2.8%−10.7%
Adjusted Cost of Sales Percent of Revenuescost_of_sales_pct_revenue_non_gaap
28.9%23.6%24.3%23.2%−2.9%−4.5%
Effective Tax Rate on Adjusted Incomeeffective_tax_rate_non_gaap
23.3%16.9%14.1%14.0%+77.2%−0.7%
Effective Tax Rate on Reported Incomeeffective_tax_rate
0.1%14.6%62.4%3.9%+160.0%−93.8%

Guided vs delivered

What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.

Data from company filings. Not investment advice.